BlossomHill Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. With each of our programs, we combine a deep understanding of disease and protein dynamics with our structure-based rational drug design expertise to identify the specific structural liabilities that limit existing therapies or approaches, and then design novel chemical scaffolds to directly address these limitations. Our scientific founder and the team we have assembled have a proven track record of developing innovative small molecule medicines that overcome the limitations of existing therapies, including multiple approved therapies that have delivered transformational patient outcomes.

Current securities

1. 10-Q filingSep 18, 2026
2. Results of Operations and Financial ConditionSep 18, 2026
3. Regulation FD DisclosureSep 15, 2026
4. SCHEDULE 13G filingAug 14, 2026
5. SCHEDULE 13D filingAug 13, 2026